Rate Video

EHA 2019 | Upcoming updates in multiple myeloma

Thierry Facon • 14 Jun 2019

Multiple Myeloma Carfilzomib Daratumumab Isatuximab

Thierry Facon, MD, of Lille University Hospital, Lille, France, discusses trial results and what the future holds for multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)

Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates

Thierry Facon • 14 Jun 2019

FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

Thierry Facon • 11 Jun 2015

MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM

Related Videos

CARTITUDE-1: health-related QoL with cilta-cel for myeloma

Saad Usmani • 1 Apr 2021

MAIA: dara-len-dex demonstrates prolonged PFS in multiple myeloma

Saad Usmani • 1 Apr 2021

Teclistamab in relapsed/refractory multiple myeloma

Saad Usmani • 1 Apr 2021

CAR-T for myeloma: ide-cel pending FDA approval

Nikhil Munshi • 22 Mar 2021